浅析周剂量多西紫杉醇联合顺铂二线治疗进展期胃癌的临床研究（行业资料）.doc

浅析周剂量多西紫杉醇联合顺铂二线治疗进展期胃癌的临床研究（行业资料） 文档信息 ： 文档作为关于“行业资料”中“医学资料”的参考范文，为解决如何写好实用应用文、正确编写文案格式、内容素材摘取等相关工作提供支持。正文8048字，doc格式，可编辑。质优实惠，欢迎下载！ 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：浅析周剂量多西紫杉醇联合顺铂二线治疗进展期胃癌的临床研究 2 1 资料与方法 3 2 结果 4 3 讨论 4 文2：浅析周剂量多西紫杉醇联合顺铂二线治疗进展期 6 1 资料与方法 7 2 结果 8 3 讨论 9 参考文摘引言： 10 原创性声明（模板） 11 文章致谢（模板） 12 正文 浅析周剂量多西紫杉醇联合顺铂二线治疗进展期胃癌的临床研究（行业资料） 文1：浅析周剂量多西紫杉醇联合顺铂二线治疗进展期胃癌的临床研究 The clinical study of weekly docetaxel combined withcisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer HUO W， LI Zhi-min， ZHU Xiao-min，et al. Department of Medical oncology， Dalian Central Hospital， Dalian 116030， China 【Abstract】 Objective To evaluate the efficacy and toxicity of docetaxel(TXT)plus cisplatin(DDP)for patients with metastatic or recurrent advanced gastric cancer(AGC)， previously treated with FOLFOX4 or XELOX regimen. Methods Twenty-seven patients were treated with docetaxel(35 mg/m2 on day 1 and 8)and cisplatin(20 mg/m2 on days 1 to 5)every 3 weeks. Results Of the 36 patients qualified for efficacy analysis， the overall respoe rate was %， including 10 cases of PR， 12 cases of SD and 14 cases of PD respectively. The median time to progression was months and median survival time was months. The predominant toxicity was hematologic， with neutropenia. Non-hematological toxicity was rarely severe. Conclusion Combination chemotherapy with TXT/DDP given on 2 out of 3 weeks is well tolerated and active in heavily pretreated patients with AGC， even after prior exposure to OXA and 5-FU. 【Key words】 Advanced gastric cancer(AGC); Docetaxel(TXT); Cisplatin(DDP) 胃癌是我国最常见的恶性肿瘤之一，其治疗早期以手术切除为主，但术后2年内有50%~60%患者出现转移。对已失去手术治疗时机或术后复发或转移的晚期患者，化疗是主要的治疗手段。与最佳支持治疗相比，全身化疗能显着延长生存时间，提高生存质量［1］。随着FOLFOX4或XELOX方案在胃癌术后辅助化疗及晚期胃癌中的广泛应用，如何治疗其化疗后复发或进展的患者，一直是探讨的课题。我院自2006年1月至2008年9月应用国产多西紫杉醇（艾素）联合顺铂二线治疗进展期胃癌36例，获得较好疗效。现如下。 1 资料与方法 临床资料 全组共36例，均为经病理学证实的晚期胃癌患者。男25例，女11例；年龄31～68岁，中位年龄45岁；病理类型：低分化腺癌21例，印戒细胞癌5例，未分化癌10例。其中18例为行根治术后辅助化疗